| ||||||||||||||
|
|
|||||||||||||



Departments of
*Anaesthesia,
Cardiovascular Medicine, and
Cardiothoracic Surgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia
Address correspondence and reprint requests to W. M. Weightman, Department of Anaesthesia, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009.
We conducted this study to evaluate whether there is an association between preoperative drug therapy and in-hospital mortality in patients undergoing coronary artery graft surgery. We collected data on 1593 consecutive patients undergoing coronary artery surgery. The relative risk of in-hospital mortality was determined by logistic regression with in-hospital mortality as the dependent variable, and independent variables that included known risk factors and preoperative cardioactive or antithrombotic drug treatment, i.e., age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with ß-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin. In-hospital mortality was 3.3%. The relative risk of in-hospital mortality (with 95% confidence intervals of the relative risk) associated with the following drug treatments was: nitrates 3.8 (1.59.6), ß-blockers 0.4 (0.20.8), aspirin within 5 days 1.0 (0.51.9), calcium antagonists 1.1 (0.62.1), ACE inhibitors 0.8 (0.41.5), digoxin 0.7 (0.21.8), and warfarin 0.3 (0.11.6). We conclude that in-hospital mortality is positively associated with preoperative nitrate therapy and negatively associated with ß-adrenergic blocker therapy. A significant association between in-hospital mortality and the preoperative use of calcium antagonists, ACE inhibitors, aspirin, digoxin, and warfarin was not confirmed.
Implications: We examined the association between common drug treatments for ischemic heart disease and short-term survival after cardiac surgery using a statistical method to adjust for patients' preoperative medical condition. Death after surgery was more likely after nitrate therapy and less likely after ß-blocker therapy.
This article has been cited by other articles:
![]() |
M. L. Bell, G. K. Grunwald, J. H. Baltz, G. O. McDonald, M. R. Bell, F. L. Grover, and A. L. W. Shroyer Does Preoperative Hemoglobin Independently Predict Short-Term Outcomes After Coronary Artery Bypass Graft Surgery? Ann. Thorac. Surg., November 1, 2008; 86(5): 1415 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Wijeysundera, W. S. Beattie, V. Rao, J. Ivanov, and K. Karkouti Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 755 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Srinivasan, M. J. Shackcloth, A. D. Grayson, and B. M. Fabri Preoperative {beta}-blocker therapy in coronary artery bypass surgery: a propensity score analysis of outcomes Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 495 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Ferguson Jr, E. D. Peterson, L. P. Coombs, M. C. Eiken, M. L. Carey, F. L. Grover, and E. R. DeLong Use of Continuous Quality Improvement to Increase Use of Process Measures in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial JAMA, July 2, 2003; 290(1): 49 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Chesebro, V. Fuster, F. J. Pugo, W. Karzai, H.-J. Priebe, and D. T. Mangano Aspirin and Mortality from Coronary Bypass Surgery N. Engl. J. Med., March 13, 2003; 348(11): 1057 - 1059. [Full Text] [PDF] |
||||
![]() |
P. W. C. ten Broecke, S. G. De Hert, E. Mertens, and H. F. Adriaensen Effect of preoperative {beta}-blockade on perioperative mortality in coronary surgery Br. J. Anaesth., January 1, 2003; 90(1): 27 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fillinger, S. D. Surgenor, G. S. Hartman, C. Clark, T. M. Dodds, A. J. Rassias, W. C. Paganelli, P. Marshall, D. Johnson, D. Kelly, et al. The Association Between Heart Rate and In-Hospital Mortality After Coronary Artery Bypass Graft Surgery Anesth. Analg., December 1, 2002; 95(6): 1483 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Geraci and C. K. Haan Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature? Ann. Thorac. Surg., November 1, 2002; 74(5): 1727 - 1732. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muller, A. Junger, M. Brau, M. M. Kwapisz, E. Schindler, H. Akinturk, M. Benson, and G. Hempelmann Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia record-keeping system Br. J. Anaesth., September 1, 2002; 89(3): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Ferguson Jr, L. P. Coombs, E. D. Peterson, and for the Society of Thoracic Surgeons National Adul Preoperative {beta}-Blocker Use and Mortality and Morbidity Following CABG Surgery in North America JAMA, May 1, 2002; 287(17): 2221 - 2227. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Costa, R. G. Carere, S. V. Lichtenstein, D. P. Foley, V. de Valk, W. Lindenboom, P. C.H. Roose, T. R. van Geldorp, C. Macaya, J. L. Castanon, et al. Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularization Therapies Study (ARTS) Circulation, November 27, 2001; 104(22): 2689 - 2693. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kaneko, Y. Saito, Y. Hikawa, K. Yasuda, and K. Makita Dose-dependent prophylactic effect of nicorandil, an ATP-sensitive potassium channel opener, on intra-operative myocardial ischaemia in patients undergoing major abdominal surgery Br. J. Anaesth., March 1, 2001; 86(3): 332 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Piriou, A. Aouifi, and J.J. Lehot Interet des beta-bloquants en medecine perioperatoire. Deuxieme partie: indications therapeutiques Can J Anesth, July 1, 2000; 47(7): 664 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Weightman and M. A. J. Newman Drug therapy before coronary artery operations J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 979 - 979. [Full Text] [PDF] |
||||
|